Metagenomi Therapeutics Inc
MGX
NASDAQ
Biotechnology
$1.23
USD
0.00 (0.00%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $46.31M
Volume 83.5K
Revenue
$13.56M
TTM
-59.8%
YoY
Gross Margin
100%
TTM
0.0%
YoY
Net Income
$-93.46M
TTM
-7.3%
YoY
Operating Cash Flow
$-85.49M
TTM
+11.9%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 8.5 | 8.7 | 3.9 | 1.2 | -0.3 |
YoY Growth | -57.5% | -24.8% | -59.3% | -69.8% | -103.0% |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 8.5 | 8.7 | 3.9 | 1.2 | -0.3 |
Selling, General & Administrative | 7.0 | 6.2 | 6.8 | 6.5 | 6.0 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 29.5 | 31.5 | 28.3 | 25.8 | 28.5 |
Operating Income | -21.0 | -22.8 | -24.4 | -24.6 | -28.8 |
EBITDA | -19.7 | -21.5 | -23.1 | -23.3 | -27.5 |
Other Income / Expense | -1.4 | -0.0 | -0.0 | -0.0 | 0.0 |
Total Other Income / Expense | 1.1 | 2.2 | 1.9 | 1.5 | 1.3 |
Income Before Income Taxes | -19.9 | -20.6 | -22.5 | -23.0 | -27.5 |
Income Taxes | 0.0 | -0.2 | 0.0 | 0.0 | 0.0 |
Net Income | -19.9 | -20.4 | -22.5 | -23.1 | -27.5 |
Consolidated Net Income / Loss | -19.9 | -20.4 | -22.5 | -23.1 | -27.5 |
Net Income Attributable to Common Shareholders | -19.9 | -20.4 | -22.5 | -23.1 | -27.5 |
Basic EPS | -$0.54 | -$0.55 | -$0.60 | -$0.61 | -$0.73 |
Diluted EPS | -$0.54 | -$0.55 | -$0.60 | -$0.61 | -$0.73 |
Basic Shares Outstanding | 37.2M | 37.3M | 37.5M | 37.6M | 37.7M |
Diluted Shares Outstanding | 37.2M | 37.3M | 37.5M | 37.6M | 37.7M |